Innovative drug delivery systems
Drug Delivery System
Unither's corporation vision means that we can provide your patients and customers with the best research and technology. The world leader for formulation and packaging in sterile unit doses is now also developing novel drug delivery solutions.
This includes Uniflash®, a technology exploiting the buccal transmucosal route.
By the end of 2010, Unither will be offering drug delivery solutions based on this new, non-invasive administration route, the efficacy of which is similar to that of intravenous injection.
With the technology developed, lipophilic molecules are very rapidly absorbed via the buccal mucosa (the epithelial membrane of which is lipophilic). This highly vascularised mucosa enables rapid delivery to the whole body via the sublingual and jugular veins.
This innovation can achieve much the same pharmacodynamic performance levels as in intravenous injection: it enables direct distribution to pulmonary and cardiac tissues and then (via the arterial system) to the rest of the body.
The technology means that significant dose reductions can be envisaged, since the extent of drug metabolism by the liver (the famous "first pass effect") is considerably reduced.
